To elucidate the role of STAT3 in early KM-LUAD development, we tested a selective small molecule STAT3 inhibitor, TTI-101, currently in phase II clinical trials, including treatment of idiopathic pulmonary fibrosis and hepatocellular carcinoma (NCT05671835 and NCT05440708, respectively), in a mouse model of KM-LUAD called CC-LR (31). This evidence concerns the gene STAT3 and hepatocellular carcinoma.